{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:29:52Z","timestamp":1697466592463},"reference-count":30,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2004]]},"DOI":"10.3748\/wjg.v11.i3.447","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T13:17:40Z","timestamp":1413983860000},"page":"447","source":"Crossref","is-referenced-by-count":19,"title":["Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice"],"prefix":"10.3748","volume":"11","author":[{"given":"Lin","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.1.5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2001.tb01049.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1566524033479465"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(01)80024-X"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051104"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1998.tb00655.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910610221"},{"key":"ref8","unstructured":"Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470\/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 1995;7:237-243."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/028418698423221"},{"key":"ref10","unstructured":"Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM. A novel \"patient-like\" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res 1993;53:3070-3072."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00666038"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-199710000-00006"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(02)70065-1"},{"key":"ref14","unstructured":"O'Reilly MS. The combination of antiangiogenic therapy with other modalities. Cancer J 2002;8 Suppl 1:S89-S99."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7187.853"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2613.1998.00087.x"},{"key":"ref17","unstructured":"Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989-1995."},{"key":"ref18","unstructured":"Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-1203."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-2545.","DOI":"10.1200\/JCO.1999.17.8.2541"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200303000-00013"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005718628223"},{"key":"ref23","unstructured":"Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-5147."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050466"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050773"},{"key":"ref26","unstructured":"Jia L, Yuan SZ. Progress of treatment of advanced pancreatic carcinoma with gemcitabine. Shijie Huaren Xiaohua Zazhi 1999;7:985-986."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.149"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"ref29","unstructured":"Jia L, Yuan SZ, Huang WG, Guo FF. Establishment of the model of human pancreatic carcinoma by surgical orthotopic implantation in nude mice. Guangzhou Medical J 2001;32:7-9."},{"key":"ref30","unstructured":"Jia L, Yuan SZ, Huang WG, Guo FF. Experimental study on Gemcitabine against model of pancreatic cancer by surgical orthotopic implantation in nude mice. Chin J Hepatobiliary Surg 2002;8:557-559."}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v11\/i3\/447.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T13:34:35Z","timestamp":1565962475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v11\/i3\/447.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v11.i3.447","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}